Quest Diagnostics to Showcase New Data at the American Heart Association 2018 Scientific Sessions

SECAUCUS, N.J., Nov. 9, 2018 /PRNewswire/ — Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, announced today that it will present results of three studies at the 2018 American Heart Association Scientific Sessions in Chicago.

Researchers from Quest Diagnostics and the company’s recently acquired Cleveland HeartLab performed the studies. The research covers topics ranging from best practices in laboratory testing for aiding the detection of non-functioning HDL (good cholesterol) to identifying individuals through employee wellness programs who may benefit from cholesterol reduction efforts.

Additional research, presented in an oral presentation, evaluates the effectiveness of genetic risk scores in aiding the identification and management of atrial fibrillation (AF) in high-risk patients in the prospective REVEAL study. These individuals are undergoing continuous monitoring with an implantable cardiac monitor. The study also identified the patient characteristics most predictive in developing AF.

“Heart disease is the leading cause of death for both men and women in the United States, but it is often preventable with appropriate prevention and intervention efforts aided by diagnostic insights,” said Jake Orville, General Manager, for Quest Diagnostics Cardiometabolic and Endocrinology Franchise, which includes Cleveland HeartLab. “Our research at this year’s AHA Scientific Sessions demonstrates the essential value of genetic and other forms of laboratory diagnostics in helping patients at risk for cardiometabolic disorders achieve the best possible health outcomes.”

Quest is a leader in cardiovascular diagnostic information services. In 2017, Quest announced the creation of its Cardiovascular Center of Excellence through the acquisition of Cleveland HeartLab. The Center of Excellence, based in Cleveland, combines Cleveland HeartLab’s personalized evaluation of heart disease risk based on inflammation and other markers with Quest’s Cardio IQ^® portfolio of lipid particle analysis and genetic and metabolic testing leadership.

Conventional laboratory tests to assess cardiovascular and metabolic diseases, such as lipid panels, may not identify risk in all patients. New inflammation, genetic and other biomarkers may help physicians identify at-risk patients and guide treatment protocols to improve outcomes.

Abstracts can be accessed on the AHA 2018 Scientific Sessions website at: http://www.abstractsonline.com/pp8/#!/4682

The Quest Diagnostics data being presented at this year’s annual meeting are:

Sunday, November 11, 2018

7:45 a.m. – 7:55 a.m.:

• “Genetic Risk Score Associated With Atrial Fibrillation Detected by Insertable Cardiac Monitoring in High Risk Patients: A Reveal AF Trial Sub-Study” (Oral: 215)

2 p.m. – 3:15 p.m.:

• “Employee Wellness Program Can Identify Those Who May Benefit From Cholesterol Reduction Efforts” (Poster: Su1173 / 1173)

Monday, November 12, 2018

10:30 a.m. – 11:45 a.m.:

• “A Novel Proteomic Predictor of Cholesterol Efflux Capacity Demonstrates Inverse Association With Cardiovascular Disease” (Poster: Mo3114 / 3114)

About Quest Diagnostics  
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world’s largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.

SOURCE Quest Diagnostics

For further information: Kim Gorode (Media): 973-520-2800 or Shawn Bevec (Investors): 973-520-2900